13 patents currently held

Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.

The next term ends in Jan 2028. from the record

Free plan: 3 watched companies. Pro: unlimited.

Alerts on its grants, lapses and transfers.

Ending by 2030

Jan 2028

Next term end

Patent families

When these terms end

5 yrs10 yrs20 yrs

Held patents by the year their term ends

202620272028 2029 20302031203220332034203520362037 20382039204020412042204320442045

notable patents all others Updated Nov 14, 2026 · includes USPTO assignment & status data published Nov 14, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know

Notable: the highest-ranked patents in this portfolio by citations and family size.

Notable patents

Ranked by citations and family size, against patents of the same kind granted the same year. How we rank

Notable

Methylation Markers for Diagnosing Hepatocellular Carcinoma and Lung Cancer US 10,513,739

Cited by 15 later US patents, top 25% of utility patents granted in 2019 in our data. Protection runs to 2038.

Ends Mar 2038 · High confidence Also notable

Leukemia Methylation Markers and Uses Thereof US 10,829,821

Cited by 13 later US patents, top 25% of utility patents granted in 2020 in our data. Protection runs to 2037.

Ends Feb 2037 · High confidence Also notable

Solid Tumor Methylation Markers and Uses Thereof US 10,544,467

Cited by 16 later US patents, top 25% of utility patents granted in 2020 in our data. Protection runs to 2037. A terminal disclaimer caps this term to an earlier patent's.

Ends Jul 2037 · Medium confidence

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.

1 fee due Jun 24, 2027
The maintenance fee for Methylation Markers for Diagnosing Hepatocellular Carcinoma and Lung Cancer (US 10,513,739) comes due Jun 24, 2027. Unpaid by Dec 27, 2027, it lapses early.
1 fee due Jul 28, 2027
The maintenance fee for Solid Tumor Methylation Markers and Uses Thereof (US 10,544,467) comes due Jul 28, 2027. Unpaid by Jan 28, 2028, it lapses early.

Which patents, and when each one lapses · Pro

Recent changes

1 term has ended since Aug 16, 2026

What they patent

The 5 largest of its 13 families, grouped by real patent family and labeled by the earliest filing in each. No technology classification is inferred from titles.

Methylation Markers for Diagnosing Hepatocellular Carcinoma and Lung Cancer	1 in force	to Mar 2038
Liver Cancer Methylation Markers and Uses Thereof	1 in force	to Dec 2037
Solid Tumor Methylation Markers and Uses Thereof	1 in force	to Jul 2037
Colon Cancer Methylation Markers and Uses Thereof	1 in force	to Jul 2037
Lung Cancer Methylation Markers and Uses Thereof	1 in force	to Jul 2037

Patents held now

Soonest term end first.

Patent	Title	Status	Expires	Confidence
US 7,742,774	Location-Based Text Messaging In force Term ends Jan 26, 2028 · High confidence	In force	Term ends Jan 26, 2028	High confidence
US 7,742,783	Symmetric Softkeys on a Mobile Electronic Device In force Term ends Oct 14, 2028 · High confidence	In force	Term ends Oct 14, 2028	High confidence
US 8,059,097	Shared Symbol and Emoticon Key and Methods In force Term ends Jun 26, 2029 · High confidence	In force	Term ends Jun 26, 2029	High confidence
US 7,881,976	Apparatus, Methods and Systems for Discounted Referral and Recommendation of Electronic Content In force Term ends Sep 10, 2029 · High confidence	In force	Term ends Sep 10, 2029	High confidence
US 7,962,152	Location Determination for Wireless Mobile Devices In force Term ends Feb 13, 2030 · High confidence	In force	Term ends Feb 13, 2030	High confidence
US 7,970,419	Systems, Devices and Methods for Location Determination In force Term ends Apr 6, 2030 · High confidence	In force	Term ends Apr 6, 2030	High confidence
US 8,797,267	Virtual hard keys on a wireless device In force Term ends Jun 5, 2030 · High confidence	In force	Term ends Jun 5, 2030	High confidence
US 10,829,821	Leukemia Methylation Markers and Uses Thereof held by Helio Health Inc. In force Term ends Feb 16, 2037 · High confidence	In force	Term ends Feb 16, 2037	High confidence
US 10,544,467	Solid Tumor Methylation Markers and Uses Thereof held by Helio Health Inc. In force Term ends Jul 6, 2037 · Medium confidence	In force	Term ends Jul 6, 2037	Medium confidence
US 12,351,876	Colon Cancer Methylation Markers and Uses Thereof held by Helio Health Inc. In force Term ends Jul 6, 2037 · High confidence	In force	Term ends Jul 6, 2037	High confidence

10 of 13 patents shown.

Pro members see all 13.

Pro members: see all 13 patents

Also on record, not counted in the 13: 12 patents ended · 4 applications pending · 9 applications abandoned. List them

Sources and methods

Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built

Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.

Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.

Export every term end as CSV · Pro

Helio LLC